Amira Zaroui

Médecin

Doctorant

amira.zaroui@aphp.fr

Description

Cardiologie et maladies vasculaires

Publications

2024

Broussier A, Paugam M, Liu N, Oghina S, Kharoubi M, Lafont C, Zaroui A, Galat A, Hittinger L, Teiger E, David JPhilippe, Bastuji-Garin S, Damy T. Frailty in heart failure according to the presence or absence of wild-type transthyretin cardiac amyloidosis. ESC Heart Fail. 2024.

2023

Dang J, Segaux L, Moktefi A, Stehlé T, Kharoubi M, Karoui KEl, Remy P, Grimbert P, Planté-Bordeneuve V, Guendouz S, Galat A, Mallet S, Oghina S, Chadha GDeep Singh, Zaroui A, Fanen P, Canoui-Poitrine F, Damy T, Audard V. Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study. Amyloid. 2023;30(1):38-48.
Bezard M, Kharoubi M, Galat A, Le Bras F, Poullot E, Molinier-Frenkel V, Fanen P, Funalot B, Moktefi A, Abulizi M, Deux J-F, Lemonnier F, Guendouz S, Chalard C, Zaroui A, Itti E, Hittinger L, Teiger E, Oghina S, Damy T. Real-Life Evaluation of an Algorithm for the Diagnosis of Cardiac Amyloidosis. Mayo Clin Proc. 2023;98(1):48-59.
Kharoubi M, Bezard M, Broussier A, Galat A, Gounot R, Poullot E, Molinier-Frenkel V, Fanen P, Funalot B, Itti E, Lemonnier F, Chadha GDeep Sing, Guendouz S, Mallet S, Zaroui A, Audard V, Audureau E, Le Corvoisier P, Hittinger L, Bordeneuve VPlanté, Lefaucheur J-P, Amiot A, Béquignon E, Bartier S, Leroy V, Teiger E, Oghina S, Damy T. Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis. Front Cardiovasc Med. 2023;10:1124660.
Damy T, Zaroui A, de Tournemire M, Kharoubi M, Gounot R, Galat A, Guendouz S, Funalot B, Itti E, Roulin L, Audard V, Fanen P, Leroy V, Poulot E, Belhadj K, Mallet S, Chadah GDeep Singh, Planté-Bordeneuve V, Gendre T, Chevalier X, Guignard S, Béquignon E, Bartier S, Folliguet T, Lemonier F, Audureau E, Tixier D, Canoui-Poitrine F, Lefaucheur J-P, Souvannanorath S, Authier F-J, Maupou S, Hittinger L, Molinier-Frenkel V, David J-P, Broussier A, Oghina S, Teiger E. Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France. Arch Cardiovasc Dis. 2023;116(10):433-446.
Albenque G, Bezard M, Kharoubi M, Odouard S, Lunati A, Poullot E, Zaroui A, Teiger E, Hittinger L, Audard V, Karoui KEl, Funalot B, Fanen P, Damy T, Oghina S. Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study. Amyloid. 2023;30(4):407-415.

2022

Damy T, Zaroui A, Oghina S. The challenge of managing patients with light-chain cardiac amyloidosis: the value of cardiac magnetic resonance as a guide to the treatment response. Eur Heart J. 2022;43(45):4736-4738.
Abroud H, Beldi-Ferchiou A, Audard V, Lemonnier F, Le Bras F, Belhadj K, Moktefi A, Poullot E, Karoui KEl, Dupuis J, Maarek A, Roulin L, Delfau-Larue M-H, Oghina S, Kharoubi M, Bezard M, Zaroui A, Damy T, Molinier-Frenkel V. Evaluation of a new ELISA assay for monoclonal free-light chain detection in patients with cardiac amyloidosis. EJHaem. 2022;3(3):828-837.
Jobbé-Duval A, Bezard M, Moutereau S, Kharoubi M, Oghina S, Zaroui A, Galat A, Chalard C, Hugon-Vallet E, Lemonnier F, Eyharts D, Poulot E, Fanen P, Funalot B, Molinier-Frenkel V, Audard V, Hittinger L, Delbarre MAntoine, Teiger E, Damy T. Prevalence and determinants of iron deficiency in cardiac amyloidosis. ESC Heart Fail. 2022;9(2):1314-1327.
Kharoubi M, Bodez D, Bezard M, Zaroui A, Galat A, Guendouz S, Gendre T, Hittinger L, Attias D, Mohty D, Bergoend E, Itti E, Lebras F, Hamon D, Poullot E, Molinier-Frenkel V, Lellouche N, Deux J-F, Funalot B, Fannen P, Oghina S, Arrouasse R, Lecorvoisier P, Souvannanorath S, Amiot A, Teiger E, Bougouin W, Damy T. Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival. Amyloid. 2022;29(2):79-91.
Odouard S, Abulizi M, Kharoubi M, Oghina S, Guendouz S, Zaroui A, Teiger E, Itti E, Damy T, Galat A. Tafamidis Decreases Cardiac Uptake of Tc-HMDP in Transthyretin Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2022;15(12):2149-2151.

2021

Bezard M, Oghina S, Vitiello D, Kharoubi M, Kordeli E, Galat A, Zaroui A, Guendouz S, Gilles F, Shourick J, Hamon D, Audard V, Teiger E, Poullot E, Molinier-Frenkel V, Lemonnier F, Agbulut O, Le Bras F, Damy T. Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement. PLoS One. 2021;16(9):e0257189.
Kharoubi M, Bezard M, Galat A, Le Bras F, Poullot E, Molinier-Frenkel V, Fanen P, Funalot B, Moktefi A, Lefaucheur J-P, Abulizi M, Deux J-F, Lemonnier F, Guendouz S, Chalard C, Zaroui A, Audard V, Béquignon E, Bodez D, Itti E, Hittinger L, Audureau E, Teiger E, Oghina S, Damy T. History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis. ESC Heart Fail. 2021;8(6):5501-5512.
Oghina S, Josse C, Bezard M, Kharoubi M, Delbarre M-A, Eyharts D, Zaroui A, Guendouz S, Galat A, Hittinger L, Fanen P, Teiger E, Mouri N, Montestruc F, Damy T. Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment. J Clin Med. 2021;10(21).
Bezard M, Kharoubi M, Galat A, Poullot E, Guendouz S, Fanen P, Funalot B, Moktefi A, Lefaucheur J-P, Abulizi M, Deux J-F, Gendre T, Audard V, Karoui KEl, Canoui-Poitrine F, Zaroui A, Itti E, Teiger E, Planté-Bordeneuve V, Oghina S, Damy T. Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis. Eur J Heart Fail. 2021;23(2):264-274.
Kharoubi M, Roche F, Bezard M, Hupin D, Silva S, Oghina S, Chalard C, Zaroui A, Galat A, Guendouz S, Canoui-Poitrine F, Hittinger L, Teiger E, Lefaucheur J-P, Damy T. Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis. ESC Heart Fail. 2021;8(2):1656-1665.
Deux J-F, Nouri R, Tacher V, Zaroui A, Derbel H, Sifaoui I, Chevance V, Ridouani F, Galat A, Kharoubi M, Oghina S, Guendouz S, Audureau E, Teiger E, Kobeiter H, Damy T. Diagnostic Value of Extracellular Volume Quantification and Myocardial Perfusion Analysis at CT in Cardiac Amyloidosis. Radiology. 2021;300(2):326-335.